Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert(Inserm), Antoni Ribas(University of California, Los Angeles), Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center), F. Stephen Hodi(Dana-Farber Cancer Institute), Omid Hamid(Angeles Clinic and Research Institute), Richard Kefford(The University of Sydney), Jeffrey S. Weber(Moffitt Cancer Center), Anthony M. Joshua(Princess Margaret Cancer Centre), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Tara C. Gangadhar(University of Pennsylvania), Amita Patnaik(South Texas Accelerated Research Therapeutics), Roxana Dronca(Mayo Clinic in Arizona), Hassane M. Zarour(University of Pittsburgh), Richard W. Joseph(Jacksonville College), Peter D. Boasberg(Angeles Clinic and Research Institute), Bartosz Chmielowski(University of California, Los Angeles), Christine Mateus(Inserm), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Kevin Gergich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeroen Elassaiss‐Schaap(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xiaoyun Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert Iannone(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco)
Cited by 1,759
Abstract
Related Papers
No related papers found
Powered by citation graph analysis